119 related articles for article (PubMed ID: 34677243)
1. Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer.
Beigi A; Vafaei-Nodeh S; Huang L; Sun SZ; Ko JJ
Curr Oncol; 2021 Sep; 28(5):3812-3824. PubMed ID: 34677243
[TBL] [Abstract][Full Text] [Related]
2. Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.
Galsky MD; Pal SK; Lin SW; Ogale S; Zivkovic M; Simpson J; Derleth C; Schiff C; Sonpavde G
Bladder Cancer; 2018 Apr; 4(2):227-238. PubMed ID: 29732393
[TBL] [Abstract][Full Text] [Related]
3. Physician reported treatment patterns and outcomes in metastatic bladder cancer in the USA: the CancerMPact
Bueno APA; Clark O; Turnure M; Moreira ES; Chang J; Hou N; Li S; Kim R; Kearney M; Kirker M; Kanas G
Future Oncol; 2024 Mar; 20(10):613-622. PubMed ID: 37357780
[TBL] [Abstract][Full Text] [Related]
4. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer.
Peirce V; Paskow M; Qin L; Dadzie R; Rapoport M; Prince S; Johal S
Target Oncol; 2023 Nov; 18(6):837-852. PubMed ID: 37751011
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
Bilen MA; Robinson SB; Schroeder A; Peng J; Kim R; Liu FX; Bhanegaonkar A
Oncologist; 2023 Sep; 28(9):790-798. PubMed ID: 37432283
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer.
Reesink DJ; van Melick HHE; van der Nat PB; Los M; Horenblas S; van de Garde EMW;
World J Urol; 2023 Jun; 41(6):1551-1562. PubMed ID: 37145158
[TBL] [Abstract][Full Text] [Related]
7. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Maglinte GA; Abraham P; Patel D; Shangguan T; Chau I
Clin Colorectal Cancer; 2020 Mar; 19(1):32-38.e3. PubMed ID: 31813769
[TBL] [Abstract][Full Text] [Related]
8. Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study.
Flannery K; Boyd M; Black-Shinn J; Robert N; Kamat AM
Future Oncol; 2019 Apr; 15(12):1323-1334. PubMed ID: 30942088
[No Abstract] [Full Text] [Related]
9. Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.
Williams CD; Allo MA; Gu L; Vashistha V; Press A; Kelley M
PLoS One; 2023; 18(2):e0282020. PubMed ID: 36809528
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting.
Nadler E; Espirito JL; Pavilack M; Boyd M; Vergara-Silva A; Fernandes A
Clin Lung Cancer; 2018 Jul; 19(4):360-370. PubMed ID: 29576407
[TBL] [Abstract][Full Text] [Related]
11. Utilization of systemic treatment for metastatic bladder cancer in everyday practice: Results of a nation-wide population-based cohort study.
Richters A; Mehra N; Meijer RP; Boormans JL; van der Heijden AG; Smilde TJ; van der Heijden MS; Kiemeney LA; Aben KK
Cancer Treat Res Commun; 2020; 25():100266. PubMed ID: 33316557
[TBL] [Abstract][Full Text] [Related]
12. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy.
Bonafede MM; Korytowsky B; Singh P; Cai Q; Cappell K; Jariwala-Parikh K; Sill B; Parikh ND
J Gastrointest Cancer; 2020 Mar; 51(1):217-226. PubMed ID: 31011982
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
Waterhouse D; Lam J; Betts KA; Yin L; Gao S; Yuan Y; Hartman J; Rao S; Lubinga S; Stenehjem D
Lung Cancer; 2021 Jun; 156():41-49. PubMed ID: 33894493
[TBL] [Abstract][Full Text] [Related]
15. Treatment Patterns and Outcomes in Stage IV Bladder Cancer in a Community Oncology Setting: 2008-2015.
Fisher MD; Shenolikar R; Miller PJ; Fenton M; Walker MS
Clin Genitourin Cancer; 2018 Dec; 16(6):e1171-e1179. PubMed ID: 30206026
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands.
Reesink DJ; van de Garde EMW; Peters BJM; van der Nat PB; Los M; Horenblas S; van Melick HHE
Sci Rep; 2020 Sep; 10(1):15822. PubMed ID: 32978455
[TBL] [Abstract][Full Text] [Related]
18. Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study.
Wells JC; Dudani S; Gan CL; Stukalin I; Azad AA; Liow E; Donskov F; Yuasa T; Pal SK; De Velasco G; Hansen AR; Beuselinck B; Kollmannsberger CK; Powles T; McGregor BA; Duh MS; Huynh L; Heng DYC
Clin Genitourin Cancer; 2021 Aug; 19(4):354-361. PubMed ID: 33863648
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.
Sroussi M; Elaidi R; Fléchon A; Lorcet M; Borchiellini D; Tardy MP; Gravis G; Guérin M; Laguerre B; Estrade F; Delva R; Barthélémy P; Loriot Y; Lavaud P; Lebret T; Neuzillet Y; Penel N; Houede N; Pouessel D; Rousseau B; Mussat E; Gross-Goupil M; Culine S; Gauthier H; Gobert A; Roupret M; Huillard O; Tartas S; Radulescu C; Allory Y; Oudard S
Clin Genitourin Cancer; 2020 Aug; 18(4):295-303.e3. PubMed ID: 31882335
[TBL] [Abstract][Full Text] [Related]
20. Third-line treatment options in metastatic pancreatic cancer patients: a real-world study.
Lu HR; Zhu PF; Deng YY; Chen ZL; Yang L
Front Oncol; 2023; 13():1251258. PubMed ID: 37810973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
